PACRGL

Across TCGA pan-cancer cohorts, PACRGL RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PACRGL’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PACRGL RNA is repressed in tumor relative to normal tissue. In most cancer types PACRGL is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, LIHC, and CHOL are the cancer types where PACRGL tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PACRGL RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.522	<.001	10	view →
LIHC	Female	All	+0.644	<.001	8	view →
CHOL	Female	All	+2.280	<.001	5	view →
KICH	Female	All	−0.943	<.001	5	view →
COAD	All	II,III,IV	+0.363	.003	5	view →
LUAD	Male	All	+0.346	.015	4	view →
BRCA	Female	All	−0.228	.001	4	view →
KIRP	All	IV	+0.639	.038	2	view →
STAD	All	II,III,IV	+0.471	.016	2	view →
ESCA	All	All	+0.442	.027	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PACRGL–THCA

Open the THCA breakdown →